Methods and compositions for inhibiting and treating neurological conditions
AssigneePopulation Bio, Inc.
InventorsEli HATCHWELL, Peggy EIS
Life of this patent
Estimating the term…
Abstract
This document provides methods and materials related to treating subjects having specific genetic variations associated with neurological disorders such as Parkinson's disease.
Claims61
A method of diagnosing a susceptibility to a movement disorder such as Parkinson's Disease in a subject, comprising:
- providing nucleic acid sequence information from the subject on the presence or absence of at least genetic variation in one or more genes or regions in FIG. 8A or FIG. 8D;
- and diagnosing a susceptibility to the movement disoder in the subject if the subject has at least one genetic variation in the one or more genes or regions in FIG. 8A or FIG. 8D, wherein the at least genetic variation occurs in the gene or region more frequently in a population of subjects that have movement disorder than in a population of subjects that does not have movement disorder.
A method of screening a subject for a genetic variation that disrupts or modulates one or more genes in FIG. 10A or FIG. 10D, comprising:
- assaying a nucleic acid sample obtained from the subject for a genetic variation in one or more genes in FIG. 10A or FIG. 10D, wherein the genetic variation is associated with a neurological or movement disorder or an altered susceptibility to a neurological or movement disorder, and detecting genetic variations that disrupt or modulate the one or more genes.
A kit, array or panel for screening for a neurological disorder in subject, the kit, array or panel comprising reagents for assaying a nucleic acid sample from a subject for the presence of a genetic variation encoded by any one of SEQ ID Nos 1-197 or 806-916 or sub-regions thereof as set forth in FIG. 9A or FIG. 9D;
- wherein the genetic variation disrupts or modulates a genomic sequence encoded by SEQ ID Nos 198 to 805 or 908 to 1042, or an RNA transcript or polypeptide expressed therefrom.
A method of preventing, inhibiting or treating a subject for a movement disorder such as Parkinson's Disease, comprising:
- providing nucleic acid sequence information from a subject at risk of, or having or suspected of having, the movement disorder including nucleic acid sequence information on one or more genes or regions in FIG. 8A or FIG. 8D;
- identifying in the subject at least one genetic variation in the one or more genes or regions;
- selecting an agent or a combination of agents that modulates the one or more genes or regions;
- and administering the selected agent or the selected combination of agents in an amount effective to prevent, slow the progression of, or treat one or more symptoms of the movement disorder in the subject.
A method of preventing, inhibiting or treating a symptom of a neurological disease in a subject, comprising:
- providing nucleic acid sequence information from a subject at risk of, or having or suspected of having, a neurological disease including nucleic acid sequence information on one or more genes or regions in FIG. 8B or FIG. 8C;
- identifying in the subject at least one genetic variation in the one or more genes or regions;
- and administering one or a combination of agents that includes a cofactor, whey, a B vitamin, a carotene, a chloroacetic acid or a salt thereof, a dicarboxylic acid or a salt thereof, a vitamin K, a nucleoside, a mineral, Butcher's broom (Ruscus aculeatus), curcumin, luteolin, epigallocatechin-3-gallate (antioxidant in white and green tea);
- thiamine, alcohol, low/no protein diets, protein supplements such as MSUD Express (manufactured by Vitaflo) that are free from branched chain amino acids leucine, isoleucine and valine, L-carnitine, salvianolic acid B, Momordica charantia (bitter melon), nicotinamide riboside, taurine, vitamin D, acetyl-L-carnitine, harpagoside, biotin, carnosine, aspirin, supplements containing antioxidants, vitamins, and other compounds such as B vitamins (B1, B2, B3, B5, B6, and/or B9), vitamin C, vitamin E, vitamin K, acetyl L-carnitine, alpha-lipoic acid, arginine, biotin, coenzyme Q10 (e.g., in the form of ubiquinol), creatine, glycerophosphocholine, glycine, nicotine adenine dinucleotide (NADH), omega-3 fatty acids (e.g., DHA), phosphatidylserine;
- high fat (ketogenic) diet, or inosine supplementation, in an amount effective to prevent, inhibit or treat at least one symptom of the neurological disease in the subject.
A method of screening a subject for a genetic variation that disrupts or modulates one or more genes in any of FIG. 7, FIG. 11D or FIG. 12, comprising:
- assaying a nucleic acid sample obtained from the subject for a genetic variation in one or more genes in FIG. 7, FIG. 11D or FIG. 12, wherein the genetic variation is associated with a decreased susceptibility to developing a neurological or movement disorder or symptoms associated with the disorder.
Dependencies are inferred from the claim text.